Keishi Adachi

This inventor holds 5 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 6 EPO patents. Top assignees: Yamaguchi University, National University Corporation Totori University. Active years: 2019-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Keishi Adachi. Retrieved from https://idiyas.com/inventor/keishi-adachi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 11)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 3.2

ph-index = 1

Forward Citations = 5(Granted Patents)

Company Filing History:

National University Corporation Totori University

patent

where one patent can have more than one assignee

Years Active: 2019-2024

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11931381 - Immunocompetent cell and expression vector expressing regulatory factors of immune function (2024-03-19),

2. 11617765 - Enhancer for T-cells or B-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in T-cells or B-cells (2023-04-04),

3. 11337997 - Immunocompetent cell and expression vector expressing regulatory factors of immune function (2022-05-24),

4. 10906984 - CAR expression vector and CAR-expressing T cells (2021-02-02),

5. 10316102 - Car expression vector and car-expressing T cells (2019-06-11),

Title: The Innovations of Inventor Keishi Adachi

Introduction

Keishi Adachi, an accomplished inventor based in Yamaguchi, Japan, is known for his significant contributions to the field of immunology. With a total of five patents to his name, Adachi has focused his research on enhancing the immune response against cancer. His innovative work aims to develop novel therapies that improve the efficacy of immunocompetent cells.

Latest Patents

Adachi's latest patents are centered on providing immunocompetent cells that express regulatory factors to enhance immune function. One of his notable inventions is an immunocompetent cell that expresses a cell surface molecule, which specifically recognizes cancer antigens, interleukin 7 (IL-7), and CCL19. This invention aims to create T cells capable of recognizing cancer cells effectively and maintaining their viability and proliferative potential.

Another significant patent by Adachi involves the development of an enhancer for T-cells and B-cells that have memory functions, as well as a malignant tumor recurrence inhibitor. This invention features a nucleic acid delivery vehicle that encodes interleukin-7 (IL-7) and CCL19, facilitating the induction of memory functions in T-cells or B-cells. Such advancements aim at prolonging the immune system's ability to reject malignant tumors over extended periods.

Career Highlights

Throughout his career, Keishi Adachi has been affiliated with esteemed institutions, including Yamaguchi University and the National University Corporation Tottori University. His dedication to advancing cancer immunotherapy has not gone unnoticed, as his innovative approaches are paving the way for new treatment methodologies.

Collaborations

Adachi's work has led him to collaborate with notable professionals in the field, including his coworkers Koji Tamada and Yukimi Sakoda. These collaborations have further enriched his research and the development of innovative solutions for enhancing immune responses against cancer.

Conclusion

Keishi Adachi’s innovative contributions in the realm of immunology demonstrate his commitment to developing advanced solutions for combatting cancer. His patents are a testament to his dedication to enhancing the body's immunocompetent cells and providing long-term efficacy against malignant tumors. As research continues to evolve, Adachi's work remains pivotal in shaping future cancer therapies.

Profile summary based on public USPTO records.